title: Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemotherapy.
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Takuya
authors.initials: T
authors.lastname: Miyagawa
authors.affiliation: Department of Dermatology, St Marianna University School of Medicine, Kawasaki, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Kadono
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kimura
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Saigusa
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Ayumi
authors.initials: A
authors.lastname: Yoshizaki
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Tomomitsu
authors.initials: T
authors.lastname: Miyagaki
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yamada
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Masui
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Hideki
authors.initials: H
authors.lastname: Fujita
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
mesh_terms: D000005:Abdomen; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D003606:Dacarbazine; D003841:Deoxycytidine / Q000031:analogs & derivatives; D018223:Dermatofibrosarcoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000601:surgery; D000077143:Docetaxel; D004317:Doxorubicin; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D006801:Humans; D007069:Ifosfamide; D007191:Indazoles; D008297:Male; D015080:Mesna; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000601:surgery; D013449:Sulfonamides / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; D003841:Deoxycytidine; D000077143:Docetaxel; D003606:Dacarbazine; C516667:pazopanib; D004317:Doxorubicin; D015080:Mesna; D007069:Ifosfamide; D000093542:Gemcitabine